Solvent-Free Synthesis of Acridone Based Dihydropyrazine Derivatives Using CuFe2O4 Nanoparticles as Heterogeneous Catalyst: Molecular Docking and In-vitro Studies as Anticancer Agents

Nowadays, acridone based heterocycles have attracted the attention of the scientific community as these are one of the most important structural moieties in the domains of pharmacy and medicinal chemistry due to their broad biological actions. Because of their planar structure, acridones can more ea...

Full description

Saved in:
Bibliographic Details
Published in:Journal of inorganic and organometallic polymers and materials 2023-12, Vol.33 (12), p.4039-4051
Main Authors: Veligeti, Rajkumar, Anireddy, Jaya Shree, Madhu, Rajesh Bagepalli, Bendi, Anjaneyulu, Praveen, P. Lakshmi, Ramakrishna, D. S.
Format: Article
Language:English
Subjects:
Anticancer properties
Cancer
Catalysts
Chemistry
Chemistry and Materials Science
Copper ferrite
Inorganic Chemistry
Molecular docking
Nanoparticles
Nucleotides
Organic Chemistry
Planar structures
Polymer Sciences
Solvents
Synthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nowadays, acridone based heterocycles have attracted the attention of the scientific community as these are one of the most important structural moieties in the domains of pharmacy and medicinal chemistry due to their broad biological actions. Because of their planar structure, acridones can more easily form complexes with DNA and RNA chains and interact with nucleotides more readily, making them effective anticancer agents. In this connection, we have introduced an efficient solvent free protocol for the synthesis of acridone based dihydropyrazine derivatives using reusable CuFe 2 O 4 magnetic nanoparticles as a heterogeneous catalyst. The in-vitro evaluation of all these compounds revealed that the compounds are active against MDA-MB-231 (human breast adenocarcinoma cell line), HEK293 (human embryonic kidney normal cell line), and IMR 32 (human neuroblastoma cell line). In addition, molecular docking studies of all acridone derivatives have been studied against 1IGT, 2VWD and 1YYH proteins. This study expanded the previous selection of additional nitrogen heterocyclic fused acridone derivatives as anticancer drugs by including dihydropyrazine moiety with different fluoro or trifluoro methyl substituted benzyl groups.
ISSN:1574-1443
1574-1451
DOI:10.1007/s10904-023-02638-4